Natco Pharma Ltd
Ticker: NATCOPHARM
Decent
71/100
☆ Add to Watchlist
Investing Reference
Price
820.25
Market Cap
14691.49
Debt/Equity
0.0367
ROE %
28.004
PB
1.9300
Promoter %
49.484
Pledge %
0.000
1Y Rev Growth %
15.922
5Y Rev Growth %
18.791
NP Margin %
39.411
NP Margin 5Y Avg %
25.452
Trading Reference
1M Return %
-6.176
6M Return %
2.027
1Y Return %
-40.964
% Away 52W High
83.481
% Away 52W Low
12.858
Daily Volume
336414
Investment Verdict
Buy
Score 89/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Natco Pharma Ltd is currently trading near a key support level, with recent price action showing bullish momentum as it approaches the 50-day EMA. If it breaks above the resistance at 800, there is a potential upside of 15%. However, if it falls below the support level of 700, there could be a downside risk of 10%.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
C
CIE Automotive India Ltd
CIE Automotive India Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
A
Akzo Nobel India Ltd
Akzo Nobel India Ltd shows decent fundamentals but faces challenges in profitability and market sentiment.
View details
N
Nuvoco Vistas Corporation Ltd
Nuvoco Vistas Corporation Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
A
Allied Blenders and Distillers Ltd
Allied Blenders and Distillers Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
B
Bls International Services Ltd
Bls International Services Ltd shows potential but has several risks that need to be addressed for sustainable growth.
View details
D
Data Patterns (India) Ltd
Data Patterns (India) Ltd shows potential for growth in a future-ready sector, but valuation concerns and execution risks warrant caution.
View details
C
City Union Bank Ltd
City Union Bank Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
View details
N
Niva Bupa Health Insurance Company Ltd
Niva Bupa Health Insurance Company Ltd shows potential for growth in a favorable sector, but faces challenges in profitability and valuation metrics.
View details
T
Transformers and Rectifiers (India) Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Rainbow Children's Medicare Ltd
Rainbow Children's Medicare Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
S
Supreme Petrochem Ltd
Supreme Petrochem Ltd shows potential for growth but faces challenges that may impact its performance. Investors should proceed with caution.
View details
E
Elgi Equipments Ltd
Elgi Equipments Ltd shows a decent investment potential with consistent growth and profitability metrics, although some risks and governance concerns exist.
View details
T
Trident Ltd
Trident Ltd shows potential but faces challenges in growth consistency and valuation metrics. Investors should proceed with caution.
View details
F
Fine Organic Industries Ltd
Fine Organic Industries Ltd shows a decent investment potential with strong growth and profitability metrics, but caution is advised due to valuation concerns and some governance issues.
View details
S
Swan Corp Ltd
Swan Corp Ltd presents several risks and lacks strong growth and profitability metrics, making it a risky investment.
View details
P
PCBL Chemical Ltd
PCBL Chemical Ltd shows potential with a decent growth outlook, but faces challenges in profitability and execution risks.
View details
Business Overview
Natco Pharma Ltd is a leading Indian pharmaceutical company dedicated to developing high-quality generic and specialty medicines. With a strong focus on affordability and accessibility, Natco serves patients and healthcare providers across India and beyond. The company is committed to innovation, ensuring that life-saving medications are available to those who need them most. Through strategic partnerships and a robust pipeline, Natco continues to expand its impact in the global healthcare landscape.
- Leading player in generic pharmaceuticals
- Focus on affordable healthcare solutions
- Strong commitment to research and development
- Expanding global presence through partnerships
- Dedicated to improving patient access to medicines
Investment Thesis
Natco Pharma Ltd stands out with a robust promoter group known for integrity and strategic vision. The company's digital services are poised for significant growth, enhancing its market position. Additionally, Natco's current valuation presents an attractive opportunity compared to its peers, making it a compelling investment choice for retail investors.
- Strong promoter credibility ensures effective management and strategic direction.
- Digital services segment shows promising growth potential, diversifying revenue streams.
- Attractive valuation compared to industry peers enhances investment appeal.
- Established presence in generics and specialty pharmaceuticals supports long-term growth.
- Commitment to R&D positions Natco for innovation and competitive advantage.
Opportunity vs Risk
Opportunities
- Strong product pipeline
- Expanding international presence
- Growing generics market
- Strategic partnerships
- R&D investment potential
Risks ⚠️
- Regulatory challenges
- Intense competition
- Currency fluctuations
- Supply chain disruptions
- Patent expirations
Peer Perspective
Natco Pharma Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin concerns. A stabilization in margins could trigger a rerating, aligning its valuation closer to industry averages.
Future Outlook
Natco Pharma Ltd is well-positioned for growth, driven by its robust pipeline and expanding market presence. Successful execution of its strategies and effective cost control will be crucial to maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Natco Pharma do?A: Natco Pharma is an Indian pharmaceutical company specializing in generic drugs and active pharmaceutical ingredients.
- Q: Is Natco Pharma a good investment?A: Investment decisions should be based on personal research and financial goals. Consult a financial advisor.
- Q: What are the key products of Natco Pharma?A: Natco Pharma offers a range of products including oncology, anti-diabetic, and cardiovascular medications.
- Q: How has Natco Pharma performed recently?A: Recent performance can vary; check financial news and reports for the latest updates.
- Q: What risks are associated with investing in Natco Pharma?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical industry.
📊 Stock Investment Checklist (100 Points)
Natco Pharma Ltd • Updated: 2025-09-17 04:02:49
-
10BusinessHighPharmaceutical sector is essential and growing, but competition is intense.
-
10GrowthHighConsistent revenue growth observed, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF has shown volatility.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighModerate debt levels, but liquidity ratios are healthy.
-
9GovernanceHighPromoter holding is strong, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed with low liquidity.
Final Score & Verdict
Score 71 / 100
• Decent
Natco Pharma Ltd shows decent potential with a solid business model and growth prospects, but faces challenges in profitability and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100